# The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia

> **NCT03201848** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Qidong Gaitianli Medicines Co., Ltd** · enrollment: 216 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** Huaiqihuang Granule

## Key facts

- **NCT ID:** NCT03201848
- **Lead sponsor:** Qidong Gaitianli Medicines Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-16
- **Primary completion:** 2023-10-14
- **Final completion:** 2024-06-30
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201848, "The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03201848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*